Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 8/20 | 0.53 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.50 |
| ▸ | PIM1 | P11309 | 2/20 | 0.50 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.50 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.50 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.50 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.50 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.50 |
| ▸ | ABL1 | P00519 | 2/20 | 0.50 |
| ▸ | BCL6 | P41182 | 2/20 | 0.50 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.50 |
| ▸ | CLK2 | P49760 | 1/20 | 0.50 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.50 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.50 |
| ▸ | HIPK4 | Q8NE63 | 1/20 | 0.50 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.50 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.50 |
| ▸ | CSNK1G1 | Q9HCP0 | 1/20 | 0.50 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.50 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1896427 | 0.86 | TTBK1 (0.55) | EGFRTTBK1TTBK2HTTMAPT | |
| SCHEMBL3061494 | 0.83 | EGFR (0.62) | EGFRABL1TTBK1TTBK2ERBB2 | |
| SCHEMBL17815581 | 0.83 | EGFR (0.49) | EGFRTTBK1TTBK2MAPTLMNA | |
| SCHEMBL17815587 | 0.83 | GALR3 (0.58) | EGFRTTBK1TTBK2MAPK1HTT | |
| SCHEMBL17815594 | 0.83 | EGFR (0.47) | EGFRAURKBCLK4MKNK2TTBK1 | |
| SCHEMBL6237775 | 0.81 | EGFR (0.61) | EGFRAURKBERBB2ABCG2 | |
| SCHEMBL839219 | 0.79 | TTBK1 (0.57) | EGFRTTBK1TTBK2MAPK1HTT | |
| SCHEMBL769494 | 0.79 | EGFR (0.54) | EGFRTTBK1 | |
| SCHEMBL9726894 | 0.79 | ABCG2 (0.54) | EGFRDYRK1ATTBK1TTBK2ERBB2 | |
| SCHEMBL855999 | 0.79 | EGFR (0.54) | EGFRMAP4K4PIM1MAP4K2DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10414768-B2 | Compounds for treating cystic fibrosis | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2019-09-17 | — | — | US | disclosed |
| US-10414768-B2 | Compounds for treating cystic fibrosis | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2019-09-17 | — | — | US | disclosed |
| US-20170362239-A1 | COMPOUNDS FOR TREATING CYSTIC FIBROSIS | UNIVERSITE PIERRE ET MARIE CURIE - PARIS 6 (UPMC) (FR) | 2017-12-21 | — | — | US | disclosed |
| US-20170362239-A1 | COMPOUNDS FOR TREATING CYSTIC FIBROSIS | UNIVERSITE PIERRE ET MARIE CURIE - PARIS 6 (UPMC) (FR) | 2017-12-21 | — | — | US | disclosed |
| US-20170362239-A1 | COMPOUNDS FOR TREATING CYSTIC FIBROSIS | UNIVERSITE PIERRE ET MARIE CURIE - PARIS 6 (UPMC) (FR) | 2017-12-21 | — | — | US | disclosed |
| WO-2016087665-A2 | COMPOUNDS FOR TREATING CYSTIC FIBROSIS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2016-06-09 | — | — | WO | disclosed |
| WO-2015078799-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-06-04 | — | — | WO | disclosed |
| US-8785453-B2 | Arylpiperazine-containing purine derivatives and uses thereof | GREEN CROSS CORPORATION (KR) | 2014-07-22 | — | — | US | disclosed |
| US-8785453-B2 | Arylpiperazine-containing purine derivatives and uses thereof | GREEN CROSS CORPORATION (KR) | 2014-07-22 | — | — | US | disclosed |
| US-8785453-B2 | Arylpiperazine-containing purine derivatives and uses thereof | GREEN CROSS CORPORATION (KR) | 2014-07-22 | — | — | US | disclosed |
| US-20120232090-A1 | ARYLPIPERAZINE-CONTAINING PURINE DERIVATIVES AND USES THEREOF | GREEN CROSS CORPORATION (KR) | 2012-09-13 | — | — | US | disclosed |
| US-8236809-B2 | Substituted 1,2,3-triazolopyrimidines for the inhibition of NAD(P)H oxidases and platelet activation | VASOPHARM GMBH (DE) | 2012-08-07 | — | — | US | disclosed |
| CN-1989140-B | Compounds containing a n-heteroaryl moiety linked to fused ring moieties for the inhibition of nad(p)h oxidases and platelet activation | VASOPHARM BIOTECH GMBH | 2012-01-11 | — | — | CN | disclosed |
| WO-2011059207-A2 | ARYLPIPERAZINE-CONTAINING PURINE DERIVATIVES AND USES THEREOF | GREEN CROSS CORPORATION (KR) | 2011-05-19 | — | — | WO | disclosed |
| WO-2011059207-A2 | ARYLPIPERAZINE-CONTAINING PURINE DERIVATIVES AND USES THEREOF | GREEN CROSS CORPORATION (KR) | 2011-05-19 | — | — | WO | disclosed |
| US-20080044354-A1 | Compounds Containing a N-Heteroaryl Moiety Linked to Fused Ring Moieties for the Inhibition of Nad(P)H Oxidases and Platelet Activation | VASOPHARM GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
| CN-1989140-A | Compounds containing a n-heteroaryl moiety linked to fused ring moieties for the inhibition of nad(p)h oxidases and platelet activation | VASOPHARM BIOTECH GMBH (DE) | 2007-06-27 | — | — | CN | disclosed |
| EP-1756113-A1 | COMPOUNDS CONTAINING A N-HETEROARYL MOIETY LINKED TO FUSED RING MOIETIES FOR THE INHIBITION OF NAD(P)H OXIDASES AND PLATELET ACTIVATION | Vasopharm Biotech GmbH (DE) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005111041-A1 | COMPOUNDS CONTAINING A N-HETEROARYL MOIETY LINKED TO FUSED RING MOIETIES FOR THE INHIBITION OF NAD(P)H OXIDASES AND PLATELET ACTIVATION | VASOPHARM BIOTECH GMBH (DE) | 2005-11-24 | — | — | WO | disclosed |
| EP-1598354-A1 | Compounds containing a N-heteroaryl moiety linked to fused ring moieties for the inhibition of NAD(P)H oxidases and platelet activation | Vasopharm Biotech GmbH (DE) | 2005-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10414768-B2 | Compounds for treating cystic fibrosis | CFTR, ABCB11, SLC26A4 | EGFR 1817/4885MAP4K4 3526/4885PIM1 1613/4885 |
| US-20120232090-A1 | ARYLPIPERAZINE-CONTAINING PURINE DERIVATIVES AND USES THEREOF | ADORA2A, P2RX5, PNP | EGFR 4696/4885MAP4K4 2781/4885PIM1 4541/4885 |
| US-20170362239-A1 | COMPOUNDS FOR TREATING CYSTIC FIBROSIS | CFTR, ABCB11, SLC26A4 | EGFR 1817/4885MAP4K4 3526/4885PIM1 1613/4885 |
| US-20080044354-A1 | Compounds Containing a N-Heteroaryl Moiety Linked to Fused Ring Moieties for the Inhibition of Nad(P)H Oxidases and Platelet Activation | NQO1, CYBB, NADK | EGFR 3890/4885MAP4K4 1984/4885PIM1 2401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.